Aardvark Therapeutics, Inc. (AARD)
Nasdaq: AARD · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2019
Who owns Aardvark Therapeutics, Inc.
As filed with the SECHolders of 5% or more
4
Xiangmin Cui holds 18.3% of Common Stock, par value $0.00001 per share, as its SCHEDULE 13G filed Feb 24, 2025 says.
Directors and officers
9
report now, of 9 people on the record since 2025. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Xiangmin Cui
SCHEDULE 13G · filed Feb 24, 2025 · Common Stock, par value $0.00001 per share
Tien-Li Lee
SCHEDULE 13G · filed May 15, 2025 · Common Stock, par value $0.00001
Vickers Venture Fund VI Pte. Ltd.
SCHEDULE 13G · filed Feb 24, 2025 · Common Stock
Kenneth Griffin
SCHEDULE 13G · filed Feb 24, 2025 · Common Stock, par value $0.00001 per share (the "Shares")
What AARD reports owning in othersstakes of 5% or more, and other ties
2 subsidiaries in 1 country, from the list filed with the 10-K filed Mar 23, 2026.
Insider tradesForm 4
2sales
2purchases
2sales on a scheduled plan
1people selling
$400,000sold, in dollars
$100,000bought, in dollars
Open-market trades on Form 4 from Nov 10, 2025 to Nov 10, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 10, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window2 of 17 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Sun Nelson | See Remarks | 2 | $400,000 | 2 | 1 | $0 |
| Lee Tien-Li | Chief Executive Officer | 0 | $0 | 0 | 1 | $100,000 |